
  
    
      
        
        We_PRP appreciate_VBP Dr_NNP ._. Miller_NNP 's_POS contribution_NN to_TO this_DT debate_NN [_NN 1_CD ]_NN ._. Whether_IN one_CD uses_VBZ his_PRP$ phrase_NN
        “ established_VBD treatment_NN” or_CC “ proven_VBN therapy_NN ,_,” we_PRP urge_VBP caution_NN in_IN using_VBG such_JJ a_DT litmus_NN test_NN to_TO
        decide_VB whether_IN the_DT use_NN of_IN placebo_NN is_VBZ or_CC is_VBZ not_RB acceptable_JJ ._. Such_JJ terms_NNS beg_VB to_TO be_VB defined_VBN
        carefully_RB ._. Should_MD nonsteroidal_NN anti-inflammatory_JJ drugs_NNS be_VB considered_VBN “ proven_VBN” for_IN
        arthritis_NN ,_, despite_IN their_PRP$ problems_NNS with_IN assay_NN sensitivity_NN [_NN 2_CD ,_, 3_CD ]_NN ?_. Dr_NNP ._. Miller_NNP states_NNS that_IN
        there_EX is_VBZ no_DT established_VBN treatment_NN for_IN adenomatous_JJ polyps_NNS ._. However_RB ,_, there_EX is_VBZ evidence_NN from_IN
        epidemiological_JJ studies_NNS and_CC clinical_JJ trials_NNS supporting_VBG the_DT use_NN of_IN aspirin_NN and_CC other_JJ
        nonsteroidal_NN anti-inflammatory_JJ drugs_NNS for_IN this_DT condition_NN [_NN 4_CD –_NN 10_CD ]_NN ._. Armed_NNP with_IN such_JJ
        evidence—whether_NN it_PRP qualifies_VBZ aspirin_NN as_IN “ proven_VBN therapy_NN” is_VBZ open_JJ to_TO subjective_JJ
        interpretation—many_NN placebo_NN opponents_NNS ,_, we_PRP maintain_VBP ,_, would_MD argue_VB for_IN an_DT active-controlled_JJ
        design_NN as_IN a_DT more_RBR ethical_JJ alternative_NN to_TO the_DT placebo-controlled_JJ design_NN actually_RB used_VBD in_IN
        APPROVe_NNP [_NN 11_CD ]_NN ._.
        Dr_NNP ._. Miller_NNP focuses_VBZ on_IN the_DT question_NN of_IN defending_VBG the_DT use_NN of_IN placebo_NN in_IN the_DT APPROVe_NNP study_NN ._.
        This_DT focus_NN reflects_VBZ the_DT prevailing_VBG bias_NN ,_, which_WDT is_VBZ to_TO choose_VB when_WRB it_PRP is_VBZ acceptable_JJ to_TO use_VB
        placebo_NN rather_RB than_IN to_TO choose_VB when_WRB it_PRP is_VBZ acceptable_JJ to_TO omit_VB placebo_NN ._. This_DT bias_NN is_VBZ evident_JJ
        in_IN the_DT current_JJ version_NN of_IN the_DT Declaration_NNP of_IN Helsinki_NNP ,_, with_IN wording_NN such_JJ as_IN ,_, “ Extreme_NNP care_NN
        must_MD be_VB taken_VBN in_IN making_VBG use_NN of_IN placebo-controlled_JJ trials_NNS ._.” Thus_RB ,_, the_DT use_NN of_IN placebo_NN is_VBZ
        typically_RB presumed_VBN “ guilty_JJ until_IN proven_VBN innocent_JJ ,_,” while_IN active-controlled_JJ designs_NNS are_VBP
        presumed_VBN “ innocent_JJ until_IN proven_VBN guilty_JJ ._.” The_DT declaration_NN is_VBZ silent_JJ on_IN the_DT possibility_NN that_IN
        omitting_VBG placebo_NN can_MD lead_VB to_TO problems_NNS ,_, too_RB ,_, as_IN we_PRP have_VBP now_RB witnessed_VBN with_IN Vioxx_NNP ._.
        So_RB perhaps_RB the_DT more_RBR important_JJ question_NN should_MD be_VB whether_IN it_PRP was_VBD defensible_JJ to_TO exclude_VB
        placebo_NN in_IN the_DT VIGOR_NNP study_NN ._. Dr_NNP ._. Miller_NNP acknowledges_VBZ that_DT placebo_NN would_MD have_VB provided_VBN a_DT
        better_RB assessment_NN of_IN the_DT safety_NN signal_NN in_IN the_DT VIGOR_NNP study_NN ._. Indeed_RB ,_, because_IN placebo_NN was_VBD not_RB
        used_VBN ,_, the_DT authors_NNS were_VBD able_JJ to_TO plausibly_RB conclude_VB that_IN the_DT difference_NN between_IN the_DT two_CD
        groups_NNS was_VBD due_JJ to_TO naproxen_NN causing_VBG benefit_NN rather_RB than_IN to_TO Vioxx_NNP causing_VBG harm_NN [_NN 12_CD ]_NN ._. (_( The_DT
        plausibility_NN of_IN this_DT conclusion_NN has_VBZ since_IN been_VBN questioned_VBN [_NN 13_CD ,_, 14_CD ]_NN ._. )_) This_DT misleading_JJ safety_NN
        signal_NN only_RB delayed_VBD the_DT withdrawal_NN of_IN Vioxx_NNP ._. Its_PRP$ design_NN was_VBD superficially_RB ethical_JJ ,_, but_CC
        science_NN was_VBD not_RB advanced_VBN ,_, and_CC the_DT public_JJ health_NN was_VBD ill-served_JJ ._.
        One_PRP might_MD protest_VB that_IN these_DT comments_NNS are_VBP made_VBN with_IN the_DT benefit_NN of_IN hindsight_NN ._. It_PRP is_VBZ true_JJ
        that_IN the_DT medical_JJ community_NN at_IN large_RB did_VBD not_RB become_VB aware_JJ of_IN this_DT safety_NN issue_NN until_IN
        September_NNP 2004_CD ,_, when_WRB the_DT results_NNS of_IN the_DT placebo-controlled_JJ APPROVe_NNP study_NN were_VBD made_VBN public_NN
        and_CC Vioxx_NNP was_VBD withdrawn_VBN ._. However_RB ,_, according_VBG to_TO David_NNP Graham_NNP 's_POS testimony_NN to_TO the_DT United_NNP
        States_NNPS Senate_NNP [_NN 15_CD ]_NN and_CC a_DT report_NN on_IN internal_JJ Merck_NNP documents_NNS [_NN 16_CD ]_NN ,_, there_EX was_VBD good_JJ reason_NN for_IN
        concern_NN about_IN a_DT possible_JJ safety_NN signal_NN before_IN 1999_CD ,_, when_WRB Vioxx_NNP was_VBD approved_VBN and_CC recruitment_NN
        for_IN VIGOR_NNP began_VBD [_NN 15_CD ]_NN ._.
        If_IN the_DT VIGOR_NNP study_NN had_VBD included_VBN a_DT placebo_NN arm_NN ,_, the_DT truth_NN about_IN Vioxx_NNP could_MD have_VB been_VBN
        learned_VBN in_IN February_NNP 2001_CD instead_RB of_IN September_NNP 2004_CD [_NN 14_CD ]_NN ._. That_DT is_VBZ over_IN 180_CD weeks_NNS during_IN
        which_WDT the_DT now_RB infamous_JJ “ two_CD to_TO four_CD jumbo_JJ jetliners_NNS” were_VBD allowed_VBN to_TO continue_VB “ dropping_VBG
        from_IN the_DT sky_NN every_DT week_NN” [_NN 15_CD ]_NN ._. Using_VBG the_DT midpoints_NNS of_IN Graham_NNP 's_POS range_NN estimates_NNS ,_, this_DT works_VBZ
        out_IN to_TO 94_CD ,_, 500_CD excess_JJ heart_NN attacks_NNS and_CC strokes_NNS ,_, including_VBG 33_CD ,_, 000_CD deaths_NNS ,_, in_IN the_DT US_NNP
        alone_RB ._.
        The_DT authors_NNS of_IN the_DT VIGOR_NNP study_NN said_VBD ,_, “ We_PRP could_MD not_RB include_VB a_DT placebo_NN group_NN” [_NN 12_CD ]_NN ._. Was_VBD
        the_DT idea_NN of_IN including_VBG a_DT placebo_NN arm_NN suggested_VBD but_CC rejected_VBD as_IN “ unethical_JJ ,_,” even_RB though_IN
        rescue_NN medication_NN could_MD have_VB been_VBN used_VBN ?_. Or_CC did_VBD they_PRP take_VBP the_DT path_NN of_IN least_JJS resistance_NN in_IN
        the_DT interest_NN of_IN rapid_JJ institutional_JJ review_NN board_NN approval_NN and_CC ease_NN of_IN patient_NN recruiting_NN ?_.
        Whatever_WDT the_DT reason_NN ,_, the_DT decision_NN to_TO omit_VB placebo_NN led_VBN to_TO ambiguity_NN and_CC inaction_NN ._.
        In_IN clinical_JJ trials_NNS ,_, whether_IN one_CD looks_VBZ at_IN efficacy_NN (_( please_VB see_VB our_PRP$ opening_VBG argument_NN in_IN
        this_DT debate_NN [_NN 17_CD ]_NN )_) or_CC safety_NN ,_, omitting_VBG placebo_NN often_RB muddies_NNS the_DT scientific_JJ waters_NNS and_CC
        places_VBZ the_DT public_JJ health_NN at_IN increased_VBN risk_NN ._. Good_JJ science_NN and_CC good_JJ ethics_NNS cannot_NN be_VB divorced_VBN
        from_IN one_CD another_DT ._. We_PRP believe_VBP these_DT considerations_NNS should_MD factor_VB into_IN discussions_NNS on_IN the_DT
        ethics_NNS of_IN clinical_JJ trial_NN design_NN ._. Before_IN we_PRP experience_VBP another_DT Vioxx_NNP ,_, we_PRP hope_VBP that_IN a_DT future_JJ
        version_NN of_IN the_DT Declaration_NNP of_IN Helsinki_NNP will_MD add_VB ,_, “ Extreme_NNP care_NN must_MD be_VB taken_VBN when_WRB omitting_VBG
        placebo_NN ._.”
      
    
  
